CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing novel inhibitors targeting the GAB1 protein to combat therapy resistance in acute myeloid leukemia. By disrupting key signaling pathways, it aims to enhance treatment efficacy and provide a new therapeutic approach for this aggressive cancer.
The emergence of therapy resistance and adaptation in acute myeloid leukemia (AML) remains a major challenge, leading to treatment failure and mortality.
We and others have provided experimental evidence supporting novel idea that adaptation and resistance to therapy could be in early stages driven by signaling pathway rewiring, rather than genetic mutations.
This project aims to advance our novel GAB1 inhibitors, targeting the adaptor protein GAB1- a key regulator of multiple signaling pathways…
Masarykova univerzita
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
